Address
16305–36th Avenue North
Minneapolis, MN 55446
United States of America (the)
Phone
763 392 0767
Website
Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
September 20, 2017
| Name | Title | Pay | Year Born |
| Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | 945,218 | 1962 |
| Vicky Hahne | Chief Financial Officer | 598,079 | 1966 |
| Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | 673,781 | 1962 |
| Jodi Sievers | Head of Investor Relations & Corporate Communications | 0 | N/A |
| Sheri Smith | Acting Head of Clinical Operations | 0 | N/A |
| Igor Gorbatchevsky | Chief Medical Officer | 0 | N/A |
| Eldon C. Mayer | Chief Commercial Officer | 0 | 1961 |
| Brent Eilefson | General Counsel | 0 | N/A |
Operating as a clinical-stage biotechnology company, Celcuity Inc. is dedicated to pioneering precision cancer treatments for patients across the United States. At the heart of their approach is the CELsignia diagnostic platform, which examines live tumor cells from patients. This innovative system aims to uncover the precise cellular dysfunction fueling an individual's cancer, thereby guiding the selection of the most appropriate targeted therapeutic intervention. Among its pipeline of drug candidates is Gedatolisib, an agent engineered to selectively inhibit class I PI3K isoforms and mammalian target of rapamycin (mTOR). This therapy is being developed specifically for advanced or metastatic breast cancer patients who are hormone receptor positive and HER2-negative. Celcuity is also advancing the CELsignia MP test, a qualitative lab-developed assay designed to quantify HER2, c-Met, and PI3K signaling activity within both breast and ovarian tumor cells. The company secured a licensing agreement with Pfizer, Inc. for the development and commercialization rights pertaining to Gedatolisib. Established in 2011, Celcuity Inc. maintains its corporate headquarters in Minneapolis, Minnesota.